While market access functions have evolved, the same can’t be said for measures used to gauge the contribution of these activities on overall business. To that end, an industry working group has developed a common framework focused on the most relevant access performance metrics (APMs).
While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.
There is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
While definitions for “specialty drug” vary-and distribution and pricing/reimbursement factors remain complicated-this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.
Executives highlight approaches around recent landmark approvals for digital medicine and gene therapy.
With specialty companies getting smarter in applying their big data insights to product marketing, the true commercial potential of machine learning and predictive modeling may soon be within reach.
How low-cost drugs can succeed in the specialty pharmacy channel.
There is no magic bullet that will dramatically impact drug pricing to everybody’s liking. But a stepwise approach involving a series of reforms, including taking advantage of the next midterm elections, could point the path toward a solution.
In its 12th annual feature, Pharm Exec builds on the revamped approach it introduced last year in spotlighting notable biopharma brands, profiling a new round of products that are making waves in five key areas in healthcare and R&D.
How “patient influencers” look beyond price to help the industry evaluate newly-launched brands.
Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Groundbreaking treatment approaches call for innovative commercialization strategies.
The five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.
A potential rush of treatment options on the horizon for non-alcoholic steatohepatitis will require skillful maneuvering in this likely lucrative but uncharted therapeutic market.
Dr. Fumie Griego, the International Federation of Pharmaceutical Manufacturers and Associations’ new Assistant Director General, speaks with Pharm Exec about her mission to use IFPMA ’s international reach to find real and practical solutions to the most pressing global healthcare challenges.
There is a tremendous, untapped market of undiagnosed patients for a variety of conditions, writes John Pagliuca. But how do you identify them when they are essentially hidden from view through conventional means?
A panel of biopharma executives discuss market access and the changing dynamics in reaching physicians and healthcare professionals.
Jackie DeAngelis outlines three common mistakes that hinder access attainment when launching a new drug.
Past Lilly president and D.C. insider discusses some of the critical topics facing the U.S. healthcare industry.
Study examines why a pharma brand’s early sales are not a trusted predictor for total lifetime value-it’s about driving waves of growth.
Payers and pharma companies seek outcomes data for evidence-based reimbursement deals.
